Difference between revisions of "Bevacizumab-adcd (Vegzelga)"

Revision as of 11:36, 4 July 2023

Note: this is an FDA-approved biosimilar. The information below is reproduced from the Bevacizumab (Avastin) page, except for the details of FDA indication and the references.

General information

Class/mechanism: Monoclonal antibody that inhibits angiogenesis by binding VEGF and preventing the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells.
Route: IV
Extravasation: neutral

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

History of changes in FDA indication

2022-09-28: Approved for metastatic colorectal cancer, recurrent or metastatic nonsquamous non-small cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Based on CT-P16 3.1)

Also known as

Code name: CT-P16
Brand name: Vegzelga

References

CT-P16 3.1: Verschraegen C, Andric Z, Moiseenko F, Makharadze T, Shevnya S, Oleksiienko A, Yañez Ruiz E, Kim S, Ahn K, Park T, Park S, Ju H, Ohe Y. Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial. BioDrugs. 2022 Nov;36(6):749-760. Epub 2022 Sep 28. link to original article PubMed NCT03676192

@@ Line 41: / Line 41: @@
 ==References==
-# '''CT-P16 3.1:''' Verschraegen C, Andric Z, Moiseenko F, Makharadze T, Shevnya S, Oleksiienko A, Yañez Ruiz E, Kim S, Ahn K, Park T, Park S, Ju H, Ohe Y. Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial. BioDrugs. 2022 Nov;36(6):749-760. Epub 2022 Sep 28. [https://doi.org/10.1007/s40259-022-00552-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/36169807/ PubMed] [https://clinicaltrials.gov/study/NCT03676192 Clinical Trial Registry]
+# '''CT-P16 3.1:''' Verschraegen C, Andric Z, Moiseenko F, Makharadze T, Shevnya S, Oleksiienko A, Yañez Ruiz E, Kim S, Ahn K, Park T, Park S, Ju H, Ohe Y. Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial. BioDrugs. 2022 Nov;36(6):749-760. Epub 2022 Sep 28. [https://doi.org/10.1007/s40259-022-00552-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/36169807/ PubMed] [https://clinicaltrials.gov/study/NCT03676192 NCT03676192]
 [[Category:Drugs]]